![Page 1: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/1.jpg)
Systemic Sclerosis Interstitial Lung Disease: Best Practice Approaches to Clinical
Management
Rebecca Keith MD
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 2: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/2.jpg)
Systemic Sclerosis ILD: Best Practice Approaches to Clinical Management
• Identify clinical features and risk factors for SSc-ILD• Review Current and emerging therapies to select the
best treatment approach for patients with SSc-ILD• Evaluate best practice approaches to communicating
and educating the patient with SSc-ILD
Learning Objectives
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 3: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/3.jpg)
Interstitial Lung Diseases
• Diverse group of disorders (>150) that resultinflammation/scarring of the pulmonary parenchyma
• Similar presentation– Progressive dyspnea and dry cough– Abnormal pulmonary physiology– Abnormal CXR and/or HRCT
• Multiple Etiologies– Idiopathic– Systemic diseases (connective tissue disorders)– Drug, environmental, or occupational exposures– Genetic
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 4: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/4.jpg)
The Interstitium
The loose-binding connective tissue (peribronchovascular sheaths, interlobular septa, subpleura)
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 5: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/5.jpg)
Interstitial Lung Disease
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 6: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/6.jpg)
Systemic Sclerosis
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 7: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/7.jpg)
> 9 systemic sclerosis
van den Hoogen F, et al. Arthritis Rheum 2013; 65:2737.
ILD can develop in limited cutaneous SSc and diffuse skin disease
Cottin. Respiratory Research 2019: 20 :13Prop
erty o
f Pres
enter
Not for
Rep
roduc
tion
![Page 8: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/8.jpg)
Clinical approach when your diagnosis is a mystery
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 9: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/9.jpg)
Raghu AJRCCM 2018Prop
erty o
f Pres
enter
Not for
Rep
roduc
tion
![Page 10: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/10.jpg)
Clinical Case
• 47 year-old male • 2 years of progressive respiratory symptoms, including
dyspnea and dry cough• Underwent a CXR which demonstrated abnormalities
concerning for interstitial lung disease• Referred to pulmonary clinic for further evaluationProp
erty o
f Pres
enter
Not for
Rep
roduc
tion
![Page 11: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/11.jpg)
What should be your first step in evaluating this
patient’s interstitial lung disease further?
1. High resolution CT of chest, interstitial lung diseases protocol
2. Surgical lung biopsy3. A detailed history and physical examination4. Cryobiopsy involving two or more lobes5. Bronchoscopy and bronchoalveolar lavage
ARS Question
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 12: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/12.jpg)
Investigate
History• Systemic diseases• Occupational &
Environmental History• Drug & Medication History• Family HistoryReview of Systems• Extra-pulmonary
manifestations
Examination• Pulmonary exam• Extra-pulmonary signsLaboratories• Extra-pulmonary organ
dysfunction• Auto-immune serologiesProp
erty o
f Pres
enter
Not for
Rep
roduc
tion
![Page 13: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/13.jpg)
Additional history• Endorses hand stiffness and skin tightening over his digits• Raynaud’s • No muscle weakness
• Lifelong non-smoker• Aircraft mechanic – exposure to jet fumes• No identifiable environmental exposures identified by detailed questionnaire.
Specifically no household birds, water damaged wood or carpeting, visible mold, or down products
• No family history of ILD or CTD
• Physical Exam confirmed skin tightening involving whole digits. • Pulmonary Function Tests: FVC 77% predicted, DLCO 62% predicted
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 14: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/14.jpg)
CT Chest
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 15: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/15.jpg)
CT chest
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 16: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/16.jpg)
HRCT Features
• Basilar predominant• Peribronchovascular• Subpleural sparing• Ground glass opacities• Reticulation• Traction bronchiectasis • No honeycombing
NSIP Pattern
Cryptogenic Organizing Pneumonia
UIP PatternNSIP Pattern
(Significant Fibrosis)
NSIP Pattern (Cellular with limited fibrosis)
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 17: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/17.jpg)
What would be the next best diagnostic step?
1. Bronchoscopy with bronchoalveolar lavage and transbronchial biopsy
2. Laboratory serologic studies to evaluate for a connective tissue disease
3. Cryobiopsy4. Surgical lung biopsy5. None of the above, proceed to treatment
ARS Question
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 18: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/18.jpg)
Results, Rheumatologic Studies
• ANA 1:80• Rheumatoid factor negative• Anti-CCP negative• Anti-dsDNA negative• Anti-Ro/SSa negative• Anti-La/SSb negative• Anti-Sm negative• Anti-RNP negative• Anti-Scl70 negative• Anti-Centromere negative• RNA polymerase III positive• Myositis panel and aldolase negative
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 19: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/19.jpg)
What is your working diagnosis?
1. Unclassifiable interstitial lung disease2. Idiopathic pulmonary fibrosis3. Scleroderma associated interstitial lung
disease4. Hypersensitivity pneumonitis
ARS Question
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 20: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/20.jpg)
ACR/EULAR criteria for the classification of Systemic sclerosis
13
van den Hoogen F, et al. Arthritis Rheum 2013; 65:2737.Prop
erty o
f Pres
enter
Not for
Rep
roduc
tion
![Page 21: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/21.jpg)
What is the best initial therapy for his lung disease?
1. Prednisone 1 mg/kg with slow taper2. Mycophenolate 3. Cyclophosphamide4. Pirfenidone or Nintedanib5. Mycophenolate and Nintedanib
ARS Question
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 22: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/22.jpg)
Scleroderma Lung Study II• 142 patients randomized to MMF for 2 years or
cyclophosphamide for one year• Inclusion criteria:
– FVC 45-80%; FEV/FVC > 65%– DLCO >40%– any extent of ground glass opacities on HRCT
with or without reticulation– Disease onset within 7 years
• Primary Outcome: Change in FVC % pred– MMF 2.19% improvement– Cyclophosphamide 2.88% improvement
• Both treatments improved dyspnea, skin• Mycophenolate better tolerated
– Similar rates of adverse effects– CYC discontinued more frequently
Lancet Resp Med 2016; 708-19Prop
erty o
f Pres
enter
Not for
Rep
roduc
tion
![Page 23: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/23.jpg)
Nintedanib in Systemic SclerosisSENSCIS Trial• 576 patients with SSc randomized to nintedanib or
placebo for one year• HRCT with fibrosis >10% lungs• Disease onset within 7 years• FVC >40%• DLCO 30-89%
• Background therapy with MMF (48%), MTX (6.6%), or prednisone 10mg or less
• Primary outcome: Annual rate of decline of FVC (mL/year)
• No differences in symptoms or other clinical signs of SSc.
• Nintedanib discontinued 16% vs 8.7%• Adverse effects included diarrhea (76% vs 32%)
and LFT elevations (4.9 vs 0.7%); NEJM 2019; 2518-28
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 24: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/24.jpg)
Nintedanib in Systemic Sclerosis
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 25: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/25.jpg)
Nintedanib in Systemic Sclerosis
Nintedanib Placebo
All patients -52.4 mL -93.3 mL 41mL (95% CI 3-79mL)
Background MMF -40.2 mL -66.5 mL
No MMF therapy -63.9 mL -119.3 mL
• Effective therapies to treat interstitial lung disease in SSC (CYC, MMF)
• 48% received background therapy with MMF
NEJM 2019; 2518-28Prop
erty o
f Pres
enter
Not for
Rep
roduc
tion
![Page 26: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/26.jpg)
Nintedanib in Systemic SclerosisINBUILD trial• 663 patients with progressive fibrosing lung disease (PF-ILD)
other than IPF randomized to nintedanib or placebo• FVC >45%• DLCO 30-80%• HRCT with fibrosis >10% lungs; stratified by UIP pattern• Progression with past 2 years• Primary outcome: Annual rate of decline of FVC (mL/year)• No background therapy allowed initially—could be added if
further progression at 6 months• 25.6% had CTD-ILD; (52% had RA; 23% SSc)
NEJM Med 2019; 138:1718-1727Prop
erty o
f Pres
enter
Not for
Rep
roduc
tion
![Page 27: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/27.jpg)
NEJM Med 2019; 138:1718-1727Prop
erty o
f Pres
enter
Not for
Rep
roduc
tion
![Page 28: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/28.jpg)
Patient remains on mycophenolate mofetil at 1500 mg BID. He returns to
your clinic after 18 months noting gradually worsening shortness of breath.
FVC 4.09 (77% pred)DLCO 20.99 (62% pred)
FVC 2.68 (52% pred)DLCO 11.56 (40% pred)D
A high-resolution chest CT is obtained. Prop
erty o
f Pres
enter
Not for
Rep
roduc
tion
![Page 29: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/29.jpg)
CT Chest
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 30: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/30.jpg)
NSIP Pattern ProgressionInitial Current
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 31: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/31.jpg)
What would be the next best treatment?
1. Prednisone 1mg/kg with slow taper, continue mycophenolate2. Rituximab, continue mycophenolate3. Change to Cyclophosphamide4. Nintedanib BID, continue mycophenolate5. Pirfenidone TID, continue mycophenolate
ARS Question
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 32: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/32.jpg)
Progressive Fibrosis in Scleroderma
Considerations:• Treat inflammation in lungs?• Slow development of fibrosis with antifibrotic?• Treat extrapulmonary manifestations?
• Tolerability• Transplant eligibility
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 33: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/33.jpg)
Pirfenidone in Scleroderma-ILD
• LOTUSS Trial• Multicenter, randomized, open-
label, phase 2 tolerability study• Confirmed SSc by ACR criteria (less
than 7 years from first non-Raynaud symptom)
• HRCT with ILD within past 2 yrs• FVC ≥ 50%, DLCO ≥ 40%• Randomized 1:1 PFD 2403 mg/d (2-
or 4-wk titration) for 16 weeks• 1° endpt: Treatment-emergent AEs• 2° endpt: Exploratory disease
outcomes
Khanna D, et al. J Rheumatol 2016;43:1672-79.
• TEAEs consistent with 3 prior phase 3 RCTs in IPF (n=1247)• Severe TEAE, TE SAE, TEAE leading to d/c more common in2-wk rather than 4-wk titration
r phase 3 RCTs in IPF (n
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 34: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/34.jpg)
Pirfenidone in Systemic Sclerosis: Future Studies
• Scleroderma Lung Study (SLS) III– Phase 2 RCT, PFD + MMF vs. PBO + MMF; goal n = 150 patients– Primary endpoint: Change in FVC %predicted over 18 months– Secondary endpoints: Change in mRSS, extent/total fibrosis on
HRCT, etc.– PI: Roth (UCLA), collab: Genentech (NCT03221257)
• Phase 3 RCT, 1° endpt: relative change in FVC % over 52 weeks– PI: Zhang (Beijing Continent Pharm Co.) (NCT03856853); goal n
= 144
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 35: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/35.jpg)
What patient’s need to know• Scleroderma disease education
• Disease can range from mild to severe• Disease course if variable• Can involve many organ systems
• Skin• Vascular system – Raynaud’s• Lungs - ILD• Kidneys – Renal impairment or Renal crisis• Heart – Pulmonary hypertension• Digestive system – GERD and esophageal dysmotility• Teeth – Decreased oral opening and Sicca • Sexual health – Erectile dysfunction, vaginal dryness and constriction
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 36: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/36.jpg)
What patient’s need to know• Care is provided by a multidisciplinary team
• Rheumatologist • Pulmonologist - ILD• Pulmonologist/Cardiologist – Pulmonary Hypertension• Gastroenterologist – GERD and esophageal dysmotility
• What to expect for disease monitoring• Pulmonary physiology• Oxygen titration• 6-minute walk distance• Echo/Right heart catheterization• CT imaging• Clinical exam
• Pulmonary rehabilitation can improve exercise capacity and HRQL
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 37: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/37.jpg)
• Lung transplant can be an option for some patients with lung limited disease
• Self care is important• Supportive care for the patient’s care giver
network is important• Support groups are a good way to network and
find support
Propert
y of P
resen
ter
Not for
Rep
roduc
tion
![Page 38: Property of Not for Reproduction Presenter · Clinical Management ... •Referred to pulmonary clinic for further evaluation Property of Presenter Not for Reproduction. What should](https://reader031.vdocuments.site/reader031/viewer/2022011921/60355a8c87a8d641674b002b/html5/thumbnails/38.jpg)
Propert
y of P
resen
ter
Not for
Rep
roduc
tion